246 related articles for article (PubMed ID: 29241652)
1. Acute administration of roflumilast enhances immediate recall of verbal word memory in healthy young adults.
Van Duinen MA; Sambeth A; Heckman PRA; Smit S; Tsai M; Lahu G; Uz T; Blokland A; Prickaerts J
Neuropharmacology; 2018 Mar; 131():31-38. PubMed ID: 29241652
[TBL] [Abstract][Full Text] [Related]
2. Acute treatment with the PDE4 inhibitor roflumilast improves verbal word memory in healthy old individuals: a double-blind placebo-controlled study.
Blokland A; Van Duinen MA; Sambeth A; Heckman PRA; Tsai M; Lahu G; Uz T; Prickaerts J
Neurobiol Aging; 2019 May; 77():37-43. PubMed ID: 30776650
[TBL] [Abstract][Full Text] [Related]
3. Acute administration of roflumilast enhances sensory gating in healthy young humans in a randomized trial.
Heckman PRA; Van Duinen MA; Blokland A; Uz T; Prickaerts J; Sambeth A
Psychopharmacology (Berl); 2018 Jan; 235(1):301-308. PubMed ID: 29098341
[TBL] [Abstract][Full Text] [Related]
4. A proof of concept phase II study with the PDE-4 inhibitor roflumilast in patients with mild cognitive impairment or mild Alzheimer's disease dementia (ROMEMA): study protocol of a double-blind, randomized, placebo-controlled, between-subjects trial.
Possemis N; Verhey F; Prickaerts J; Blokland A; Ramakers I
Trials; 2024 Mar; 25(1):162. PubMed ID: 38438923
[TBL] [Abstract][Full Text] [Related]
5. An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients.
Gilleen J; Farah Y; Davison C; Kerins S; Valdearenas L; Uz T; Lahu G; Tsai M; Ogrinc F; Reichenberg A; Williams SC; Mehta MA; Shergill SS
Psychopharmacology (Berl); 2021 May; 238(5):1279-1289. PubMed ID: 30536081
[TBL] [Abstract][Full Text] [Related]
6. Effects of rolipram and roflumilast, phosphodiesterase-4 inhibitors, on hypertension-induced defects in memory function in rats.
Jabaris SG; Sumathy H; Kumar RS; Narayanan S; Thanikachalam S; Babu CS
Eur J Pharmacol; 2015 Jan; 746():138-47. PubMed ID: 25446433
[TBL] [Abstract][Full Text] [Related]
7. The Phosphodiesterase-4 Inhibitor Roflumilast, a Potential Treatment for the Comorbidity of Memory Loss and Depression in Alzheimer's Disease: A Preclinical Study in APP/PS1 Transgenic Mice.
Wang H; Zhang FF; Xu Y; Fu HR; Wang XD; Wang L; Chen W; Xu XY; Gao YF; Zhang JG; Zhang HT
Int J Neuropsychopharmacol; 2020 Dec; 23(10):700-711. PubMed ID: 32645141
[TBL] [Abstract][Full Text] [Related]
8. Preliminary evidence for the phosphodiesterase type-4 inhibitor, roflumilast, in ameliorating cognitive flexibility deficits in patients with schizophrenia.
Livingston NR; Hawkins PC; Gilleen J; Ye R; Valdearenas L; Shergill SS; Mehta MA
J Psychopharmacol; 2021 Sep; 35(9):1099-1110. PubMed ID: 33908296
[TBL] [Abstract][Full Text] [Related]
9. Roflumilast ameliorates cognitive impairment in APP/PS1 mice via cAMP/CREB/BDNF signaling and anti-neuroinflammatory effects.
Feng H; Wang C; He W; Wu X; Li S; Zeng Z; Wei M; He B
Metab Brain Dis; 2019 Apr; 34(2):583-591. PubMed ID: 30610438
[TBL] [Abstract][Full Text] [Related]
10. The effects of roflumilast, a phosphodiesterase type-4 inhibitor, on EEG biomarkers in schizophrenia: A randomised controlled trial.
Gilleen J; Nottage J; Yakub F; Kerins S; Valdearenas L; Uz T; Lahu G; Tsai M; Ogrinc F; Williams SC; Ffytche D; Mehta MA; Shergill SS
J Psychopharmacol; 2021 Jan; 35(1):15-22. PubMed ID: 32854568
[TBL] [Abstract][Full Text] [Related]
11. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
[TBL] [Abstract][Full Text] [Related]
12. Cognitive effects of methylphenidate and levodopa in healthy volunteers.
Linssen AM; Sambeth A; Vuurman EF; Riedel WJ
Eur Neuropsychopharmacol; 2014 Feb; 24(2):200-6. PubMed ID: 24119823
[TBL] [Abstract][Full Text] [Related]
13. The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses.
Vanmierlo T; Creemers P; Akkerman S; van Duinen M; Sambeth A; De Vry J; Uz T; Blokland A; Prickaerts J
Behav Brain Res; 2016 Apr; 303():26-33. PubMed ID: 26794595
[TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase-4 inhibitors ameliorates cognitive deficits in deoxycorticosterone acetate induced hypertensive rats via cAMP/CREB signaling system.
Jabaris SS; Sumathy H; Girish R; Narayanan S; Sugumar M; Saravana Babu C; Thanikachalam S; Thanikachalam M
Brain Res; 2015 Oct; 1622():279-91. PubMed ID: 26168894
[TBL] [Abstract][Full Text] [Related]
15. A Nonhuman Primate PET Study: Measurement of Brain PDE4 Occupancy by Roflumilast Using (R)-[
Takano A; Uz T; Garcia-Segovia J; Tsai M; Lahu G; Amini N; Nakao R; Jia Z; Halldin C
Mol Imaging Biol; 2018 Aug; 20(4):615-622. PubMed ID: 29441434
[TBL] [Abstract][Full Text] [Related]
16. The phosphodiesterase-4 inhibitor roflumilast decreases ethanol consumption in C57BL/6J mice.
Liu X; Hao PD; Yang MF; Sun JY; Mao LL; Fan CD; Zhang ZY; Li DW; Yang XY; Sun BL; Zhang HT
Psychopharmacology (Berl); 2017 Aug; 234(16):2409-2419. PubMed ID: 28477089
[TBL] [Abstract][Full Text] [Related]
17. The phosphodiesterase-4 inhibitor roflumilast impacts Schistosoma mansoni ovipositing in vitro but displays only modest antischistosomal activity in vivo.
Botros SS; El-Lakkany NM; Seif El-Din SH; William S; Sabra AN; Hammam OA; de Koning HP
Exp Parasitol; 2020 Jan; 208():107793. PubMed ID: 31711973
[TBL] [Abstract][Full Text] [Related]
18. Biperiden Selectively Impairs Verbal Episodic Memory in a Dose- and Time-Dependent Manner in Healthy Subjects.
Borghans L; Sambeth A; Blokland A
J Clin Psychopharmacol; 2020; 40(1):30-37. PubMed ID: 31834098
[TBL] [Abstract][Full Text] [Related]
19. Effects of a cholinergic nootropic (WEB 1881 FU) on event-related potentials recorded in incidental and intentional memory tasks.
Münte TF; Heinze HJ; Scholz M; Künkel H
Neuropsychobiology; 1988; 19(3):158-68. PubMed ID: 3059222
[TBL] [Abstract][Full Text] [Related]
20. PDE4 inhibition reduces neointima formation and inhibits VCAM-1 expression and histone methylation in an Epac-dependent manner.
Lehrke M; Kahles F; Makowska A; Tilstam PV; Diebold S; Marx J; Stöhr R; Hess K; Endorf EB; Bruemmer D; Marx N; Findeisen HM
J Mol Cell Cardiol; 2015 Apr; 81():23-33. PubMed ID: 25640159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
